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Cardiovascular diseases are a major cause of premature
death and disability. They represent an extraordinarily
strong financial burden upon health-care systems in
‘‘developed’’ countries. Elevated blood pressure is a major
cause of cardiovascular disease. There is much evidence
that cardiovascular risk increases from normal blood
pressure (i.e., from 115/75 mmHg upwards) [1]. Over-
whelming evidence shows that reducing salt intake from
9–12 g/day to 5–6 g/day lowers blood pressure [2]. Blood
pressure is a surrogate endpoint, but may be related to a
reduction of morbidity and mortality due to cardiovascular
causes. Thus, intensive support and encouragement to cut
down on the intake of salt in foods might reduce cardio-
vascular risk. Such a primary prevention strategy might
significantly reduce social and health-care costs. The meta-
analysis published simultaneously by Taylor et al. [3, 4] in
the Cochrane Database of Systematic Reviews and the
American Journal of Hypertension deals with this impor-
tant issue. Specifically, it assesses the long-term effects of
interventions aimed at reducing dietary salt upon morbidity
and mortality due to cardiovascular causes. They found 7
studies (involving 6,489 participants) that met the inclusion
criteria. Three of the seven studies focused on normoten-
sive subjects; two on hypertensives; one in a mixed pop-
ulation of normotensives and hypertensives; and one in
subjects with heart failure (n = 232). Despite the large
number of collated cardiovascular events (665 deaths
in 6,250 participants), the meta-analyses fails to show
significant differences in intervention groups compared
with controls. There is only limited evidence that dietary
advice to reduce salt intake may increase the prevalence of
deaths in people with heart failure [relative risk at the end
of the trial: 2.59; 95 % confidence interval (CI), 1.04–6.44;
21 deaths]. The authors conclude that there is insufficient
power to exclude the clinically important effects of reduced
dietary salt on mortality or cardiovascular morbidity in
normotensive or hypertensive populations. Moreover, they
state that further evidences from randomized controlled
trials would be needed to confirm if the restriction of die-
tary sodium is harmful for people with heart failure.
In a recent comment, two preventive-medicine experts,
Dr. He and Professor MacGregor [5], criticize the meta-
analysis published by Taylor et al. [3, 4]. In their opinion,
meta-analysis ‘‘reflects poorly on the reputation of the
Cochrane Library and the authors’’. The two experts make
statements regarding the fact that one trial in heart failure
did not have to be included in the meta-analysis; they
claimed that the trial was clinically heterogeneous. Indeed,
patients who had been included in that trial were severely
depleted of salt and water due to aggressive diuretic
therapy. Moreover, the experts re-analyzed the data by
combining together the results for hypertensive and nor-
motensive subjects. Their results show a significant
reduction in cardiovascular events by 20 % (pooled rela-
tive risk: 0.80; 95 % CI, 0.64–0.99). The meta-analysis was
undertaken using the fixed-effect model because the het-
erogeneity among studies did not reach the standard
probability value for significance. However, this could be
the case of ‘‘not practicing what you preach’’. Despite
accepting statistical homogeneity according to Cochrane’s
Q test (p = 0.36) and the low value of the I2 index (only
6 % diversity among trials was detected), pooling data
from two populations (hypertensives and normotensives)
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can be considered inappropriate or an artifact to more
readily demonstrable risk differences by increasing the size
of the pooled sample. We believe that conclusions about
the influence of salt intake upon cardiovascular risk in
hypertensives and normotensives must be supported by
meta-analyses in different subgroups. Nevertheless, if data
from these two populations must be pooled together, then
the random-effect model is appropriate because clinical
heterogeneity should be assumed. We re-analyzed the data
using the random-effect model (Fig. 1). In this case, dif-
ferences were not statistically significant (pooled relative
risk: 0.80; 95 % CI, 0.63–1.03; p = 0.0578). Thus, what is
heterogeneity and how should one evaluate it? The litera-
ture has highlighted heterogeneity as an important con-
struct since the origins of evidence-based medicine in the
early 1990s [6]. Heterogeneity can be defined as ‘‘any kind
of variability among studies in a systematic review’’ [7].
Heterogeneity can be associated with any of the classic
four factors (population, intervention, comparator and
outcomes), even if the timing of the measurement of out-
comes as well as the health-care setting must also be
considered. Clinical heterogeneity is present if patient-
level factors—most common variables related to patient
characteristics, location and severity of disease, comor-
bidities, and accompanying treatment—influence or mod-
ify the magnitude of the treatment effect. Heterogeneity is
also related to statistical and methodological aspects. In
particular, statistical heterogeneity can be defined as the
variability in the observed treatment effects beyond what
would be expected by random error (chance). It is assessed
by testing the null hypothesis that the studies have a
common treatment effect given a chosen P value. Statis-
tical heterogeneity may signal clinical heterogeneity,
methodological heterogeneity, or chance. If statistical
heterogeneity is detected, one cannot be sure whether to
attribute it to clinical heterogeneity, methodological het-
erogeneity, chance, or a combination of the three variables
[8]. If significant statistical heterogeneity is not detected by
different methods (i.e., Cochrane’s Q test, I2 index, meta-
regression), clinical heterogeneity can be present. Thus, an
overall test of heterogeneity may be not significant, but a
dimension of the study populations may vary significantly
among studies, and influence the study findings. Such an
analysis of population variation may also dictate: the
choice of the statistical model in meta-analyses (random or
fixed-effect models); employment of sensitivity analyses to
determine the degree and impact of the variation on the
pooled estimate; subgrouping of studies to estimate sepa-
rate pooled estimates; a decision to forego any meta-
analysis that pools data inferentially across studies [9].
Unfortunately, this is true in our case: hypertensives and
normotensives are different populations. Thus, the findings
Fig. 1 Forrest plot of outcome trials of salt reduction at longest follow-
up combining hypertensive and normotensive individuals: relative risk
of cardiovascular disease (CVD) events. Duration of follow-up ranged
from 7 months to 11.5 years. We used a random-effect model
by combining data from normotensive and hypertensive subjects.
Pooled relative risk = 0.798115 (95 % CI = 0.632276–1.007452).
Chi-squared test (test relative risk differs from 1) = 3.600484 (degree
of freedom = 1) p = 0.0578. Egger: bias = –0.37627 (95 % CI =
-7.437157 to 6.684616), p = 0.84. TOHP I Trial of hypertension
prevention, phase 1. TOHP II Trial of hypertension prevention, phase 2.
TONE Trial of nonpharmacologic interventions in the elderly. *Data
for individual trials taken from the meta-analysis from Taylor et al
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from the main analysis should be confirmed across sub-
groups because the magnitude of the effect can differ
greatly across different populations.
In conclusion, we believe that the conclusions reached
by Taylor et al. in their Cochrane systematic review are
quite balanced and based upon the facts. Moreover, a rel-
evant ‘‘take home’’ message is that statistical computation
cannot substitute for clinical reasoning and methodological
issues. The controversy between salt intake and cardio-
vascular risk remains open, and further studies are needed
to draw strong conclusions.
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